The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2025 | Challenges when treating patients with AML with transplant
Julian Ronnacker, MD, University of Münster, Münster, Germany, discusses the challenges that remain when treating patients with acute myeloid leukemia (AML) with transplant. He highlights the need to identify novel markers of post-transplant outcomes and to improve outcomes for HLA mismatched patients. Additionally, he touches on the dilemma of how to manage patients who were refractory to primary treatment. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The first thing is to define or discover novel markers which affect post-transplant outcome. APOE and APOE germline variation is a vivid example of this. And second, I think a major challenge in transplantation is the outcome of HLA mismatched patients and patients not having a fully matched donor. We need to improve their outcome, we need to reduce non-relapse deaths...
The first thing is to define or discover novel markers which affect post-transplant outcome. APOE and APOE germline variation is a vivid example of this. And second, I think a major challenge in transplantation is the outcome of HLA mismatched patients and patients not having a fully matched donor. We need to improve their outcome, we need to reduce non-relapse deaths. And this is a major obstacle in transplantation still. Another interesting question is how do we deal with patients who were refractory to primary treatment and how do we act? Do we aim to reduce leukemic burden in order to improve outcomes or is it just improving non-relapse mortality and toxicity of the transplantation? We don’t know that exactly, but there is emerging data helping us to make the best judgments and decisions.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
